/ALACT.PA
ALACT.PA Stock - Acticor Biotech SAS
Healthcare|BiotechnologyPAR
$0.25+0.00%
+$0.00 (+0.00%) • Dec 9
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.17
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.28
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALACT.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.25 – $0.25
TARGET (TP)$0.29
STOP LOSS$0.23
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.26
52W High$5.30
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-728,000 | $-86,000 | $-100,000 | $-99,000 | $-75,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-20,163,000 | $-17,779,000 | $-14,894,000 | $-9,051,000 | $-5,164,000 |
| Net Income | $-18,640,000 | $-15,878,000 | $-12,608,000 | $-7,651,000 | $-5,053,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.00 | $-1.51 | $-1.62 | $-1.20 | $-0.96 |
Company Overview
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ALACT.PABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.46
Q4 2024
EPS Surprise History
Q4 20
No data
Q4 21
No data
Q1 22
No data
Q4 22
No data
Q1 23
No data
Q4 23
No data
Q2 24
No data
Q4 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 4, 2024 | — | $-0.46 | — | — |
Q2 2024 | May 10, 2024 | — | $-0.00 | — | — |
Q4 2023 | Oct 26, 2023 | — | $-1.48 | — | — |
Q1 2023 | Mar 23, 2023 | — | $-0.81 | — | — |
Q4 2022 | Oct 27, 2022 | — | $-0.69 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-869.59 | — | — |
Q4 2021 | Oct 19, 2021 | — | $-752.02 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.66 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.54 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.48 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.48 | — | — |
Q1 2019 | Jan 31, 2019 | — | $-0.98 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.98 | — | — |
Q1 2018 | Jan 31, 2018 | — | $-1.56 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-1.56 | — | — |
Q1 2017 | Jan 31, 2017 | — | $-0.07 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.07 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.20 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-0.20 | — | — |
Q4 2014 | Dec 31, 2014 | — | $-0.15 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ALACT.PA
What is ALACT.PA's current stock price?
Acticor Biotech SAS (ALACT.PA) is currently trading at $0.25 per share. The stock has moved +0.00% today.
What is the analyst price target for ALACT.PA?
No analyst price targets are currently available for this stock.
What sector is Acticor Biotech SAS in?
Acticor Biotech SAS operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the PAR exchange.
What is ALACT.PA's market cap?
Acticor Biotech SAS has a market capitalization of $0.00 billion, making it a small-cap company.
Does ALACT.PA pay dividends?
No, Acticor Biotech SAS does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALDEI.PA
Deinove S.A.
$0.03
Mkt Cap: $0.0B
ALHYG.PA
Hybrigenics S.A.
$0.01
Mkt Cap: $0.0B
ALMDP.PA
Medesis Pharma S.A.
$0.35
Mkt Cap: $0.0B
ALNEV.PA
Neovacs S.A.
$0.01
Mkt Cap: $0.0B
ALNOX.PA
NOXXON Pharma N.V.
$0.04
0ALPHA.PA
Pharnext S.A.
$0.00
Mkt Cap: $0.0B
ALQGC.PA
Quantum Genomics S.A.
$0.07
Mkt Cap: $0.0B
ALVET.PA
TheraVet S.A.
$0.08
Mkt Cap: $0.0B
LYS.PA
Lysogene S.A.
$0.28
Mkt Cap: $0.0B
PHXM.PA
PHAXIAM Therapeutics S.A.
$0.10
Mkt Cap: $0.0B
Explore stocks similar to ALACT.PA for comparison